Biosplice Therapeutics: Biosplice announces Interim data from phase 3 longterm extension trial in knee osteoarthritis and initiates new phase 3 trial

Biosplice Therapeutics, Inc. (Biosplice), a clinical─stage biotechnology company, announced potential structure─modifying highlights from an ongoing long─term extension study, OA─07, for its knee OA drug